FINWIRES · TerminalLIVE
FINWIRES

Update: AtkinsRealis to Buy Ireland-Based Firm TOBIN; Signs 20-Year Agreement for Engineering Services With First American Nuclear

By

(Updates to add acquisition of TOBIN and shares)

AtkinsRealis Group (ATRL.TO) entered into a definitive agreement to acquire Patrick J Tobin & Co. Ltd. (TOBIN), a leading Irish engineering and project management consultancy firm, it said Wednesday. No financial details were given.

"The acquisition supports AtkinsRealis' growth strategy in Ireland, further strengthening its local footprint to over 700 employees and bolstering its capabilities to support Ireland's ambitious program of infrastructure development," the company said in a statement.

Meanwhile, earlier Wednesday, the company also signed a Strategic Alliance agreement with First American Nuclear (FANCO) whereby the company will act as the exclusive engineering, procurement, and construction management (EPCM) provider for EAGL-1 small modular reactor (SMR) projects in North America.

Work has begun on the task orders, and the agreement contemplates services worth up to $250 million over the first five years, it said. Under the first task orders, AtkinsRealis will prepare procedures and policies required to do design work, such as a quality program and engineering procedures.

The company will also undertake the conceptual design for the balance of plant and review the design of the nuclear steam supply system.

Shares of the company were last seen down 0.9% at $88.12 on the Toronto Stock Exchange.

Price: $87.79, Change: $-1.11, Percent Change: -1.25%

Related Articles

Mining & Metals

Zentek Surges 24% as ZenGuard Filters Added to Federal List For Direct Procurement

Zentek (ZEN.V), up 24% on last look, on Wednesday said its ZenGUARD air filters have been added to the federal government's Pathway to Commercialization (PTC) source list.The listing establishes Zentek as an exclusive supplier within the PTC framework to the Canadian government for three years, during which time any federal department or agency may purchase ZenGUARD directly from the company. The milestone is the culmination of a multi-year collaboration between Zentek, ISC, and the National Research Council of Canada.Inclusion on the PTC source list does not guarantee orders or contracts, a statement said.Zentek shares were last seen up $0.28 to $1.45, on the TSX Venture Exchange.Price: $1.43, Change: $+0.26, Percent Change: +22.22%

$ZEN.V
Mining & Metals

TSX Falls 230 Points at Midday in Broad Decline

The Toronto Stock Exchange is down 230 points at midday with most sectors lower.Miners and healthcare are the best performers, up 1.9% and 1.3%, respectively.Info tech is the biggest laggard, 2%.In other news, the federal and Alberta governments are likely to announce a deal on industrial carbon pricing this Friday, CTV News reports, citing unnamed sources.The sources also say Canada and Alberta are working around the idea of setting the $130-a-tonne price by 2040, as opposed to 2030, CTV notes.In stocks, Boyd Group Services (BYD.TO) is down near 12% to a multi-year low of $134.94 after it reported its first-quarter results this morning.

$^GSPTSE$.GSPTSE$BYD.TO
Mining & Metals

CIBC Confirms Outperformer Rating on kneat.com and Raises Target to $6.25 on Strategic Review Confirmation

CIBC Capital Markets maintained its outperformer rating on the shares of kneat.com (KSI.TO) and raised its price target to C$6.25 from C$5.50 after the company confirmed that it started a strategic in February 2026 to explore potential strategic options.The bank sees kneat as "attractive" for both strategic and financial buyers, given its "leading position in digital validation software for regulated industries (used by eight of the world's top 10 pharmaceutical manufacturers) and strong recurring revenue growth (~$74MM ARR, +33% Y/Y SaaS revenue in 2025)"."With strategic optionality now adding upside potential, we maintain our Outperformer rating on Kneat, and we have adjusted our valuation approach to blend our standalone intrinsic value with a scenario-weighted takeout value, resulting in a price target of $6.25 ($5.50 prior)," said analyst Erin Kyle. "We agree that ArisGlobal and Blue Mountain, which both serve major pharma customers would be logical bidders in terms of product fit and customer base."The bank also expects management to have a preference for an acquirer with experience scaling software and familiarity with the life sciences space, in a scenario where kneat decides to sell itself."Given Kneat's high gross margin and mission-critical software, we could see a scenario where a higher-than-average premium (40%-50%) is offered, resulting in 8.3x sales or $6.75/sh," said Kyle.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $5.30, Change: $+0.03, Percent Change: +0.57%

$KSI.TO